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Transplantation of BDNF-Secreting Mesenchymal Stem
Cells Provides Neuroprotection in Chronically
Hypertensive Rat Eyes
Matthew M. Harper,*,1,2,3,4 Sinisa D. Grozdanic,1,2 Bas Blits,5 Markus H. Kuehn,6
Daniel Zamzow,7 Janice E. Buss,7 Randy H. Kardon,1,6 and Donald S. Sakaguchi*,1,3,4
PURPOSE. To evaluate the ability of mesenchymal stem cells
(MSCs) engineered to produce and secrete brain-derived neu-
rotrophic factor (BDNF) to protect retinal function and struc-
ture after intravitreal transplantation in a rat model of chronic
ocular hypertension (COH).
METHODS. COHwas induced by laser cauterization of trabecular
meshwork and episcleral veins in rat eyes. COH eyes received
an intravitreal transplant of MSCs engineered to express BDNF
and green fluorescent protein (BDNF-MSCs) or just GFP (GFP-
MSCs). Computerized pupillometry and electroretinography
(ERG) were performed to assess optic nerve and retinal func-
tion. Quantification of optic nerve damage was performed by
counting retinal ganglion cells (RGCs) and evaluating optic
nerve cross-sections.
RESULTS. After transplantation into COH eyes, BDNF-MSCs pre-
served significantly more retina and optic nerve function than
GFP-MSC–treated eyes when pupil light reflex (PLR) and ERG
function were evaluated. PLR analysis showed significantly
better function (P  0.03) in BDNF-MSC–treated eyes (operat-
ed/control ratio  63.00%  11.39%) than GFP-MSC–treated
eyes (operated/control ratio  31.81%  9.63%) at 42 days
after surgery. The BDNF-MSC–transplanted eyes also displayed
a greater level of RGC preservation than eyes that received the
GFP-MSCs only (RGC cell counts: BDNF-MSC–treated COH
eyes, 112.2 19.39 cells/section; GFP-MSC–treated COH eyes,
52.21  11.54 cells/section; P  0.01).
CONCLUSIONS. The authors have demonstrated that lentiviral-
transduced BDNF-producing MSCs can survive in eyes with
chronic hypertension and can provide retina and optic nerve
functional and structural protection. Transplantation of BDNF-
producing stem cells may be a viable treatment strategy for
glaucoma. (Invest Ophthalmol Vis Sci. 2011;52:4506–4515)
DOI:10.1167/iovs.11-7346
Glaucoma is an optic neuropathy resulting in progressiveretinal ganglion cell (RGC) death and loss of visual func-
tion. Although the underlying causes of glaucoma have not
been clearly elucidated, many factors that may contribute to
the neurodegeneration of RGCs have been identified, including
reactive changes in optic nerve head glial cells,1 a decrease in
retrograde transport of vital trophic factors,2 oxidative stress
mediated by the generation of reactive oxygen species
(ROS),3,4 and excessive activation of different immune system
components.5–7 Considering that glaucoma is one of the most
frequent causes of blindness worldwide, there is an enormous
need to develop therapeutic strategies that may protect optic
nerve function and structure in this patient population.
Cell transplantation has been proposed as an experimental
strategy to treat the diseased and injured central nervous sys-
tem (CNS), including the retina. Multipotent bone marrow–
derived mesenchymal stem cells (MSCs) hold great potential
for the delivery of therapeutic proteins to treat the damaged or
diseased CNS. Transplantation of MSCs has attracted consider-
able attention in efforts to develop cell-based therapies because
they are readily obtained from the patient. Promising results
have been reported with the use of MSCs in animal models for
a number of different diseases, including spinal cord injury,8,9
stroke,10 and myelin deficiency.11 In addition, MSCs have the
ability to survive and migrate when transplanted to CNS tis-
sues,12–15 to differentiate into neural-like cells in vitro,13,15–18
and to display electrophysiological properties consistent with
mature neurons.19,20 Naive MSCs have also shown the poten-
tial to be neuroprotective when used as a therapeutic modality
in animal models of retinal degeneration21–26 and glaucoma.27
Engineering of stem cells to produce neurotrophic growth
factors has been explored as an attractive mode of long-term
delivery of neuroprotective substances to the injured CNS in
different animal models.28–30
Brain-derived neurotrophic factor (BDNF) is a 14-kDa neu-
roprotective protein31 that preferentially binds to the high-
affinity TrkB32 receptor. Target-derived BDNF from the thala-
mus is essential for correct RGC development33,34 and ex vivo
maintenance of RGCs.35,36 It has been shown that retrograde
transport of target-derived BDNF to the retina is decreased in
an animal model of acute elevation of intraocular pressure
(IOP).2 Supplemental delivery of BDNF in different animal
models has been shown to have beneficial effects on the
preservation of the retina and optic nerve structure,37–41 pro-
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viding hope that the therapeutic use of BDNF may become a
viable option for long-term treatment of glaucoma.
The principal purpose of this study was to evaluate whether
transplanted MSCs can survive in eyes with chronic hyperten-
sion and provide protection for the retina and for optic nerve
function and structure. Additionally, we wanted to determine
whether MSCs engineered to produce and secrete BDNF
would provide better functional and structural outcomes in
eyes with chronic hypertension than in eyes that received only
control MSCs.
MATERIALS AND METHODS
Animals
All animal studies were conducted in accordance with the ARVO
Statement for the Use of Animals in Ophthalmic and Vision Research,
and procedures were approved by the Iowa State University Commit-
tee on Animal Care. Adult Brown Norway rats (10 months of age,
retired breeders; n  28) and E17 rat pups (n  36) were used for
experiments. Rats were kept under a 12-hour light/12-hour dark regi-
men.
Rat Mesenchymal Stem Cells
Rat MSCs isolated from adult rats (obtained from Tulane Center for
Gene Therapy, New Orleans, LA) were maintained as an adherent cell
line in -modified Eagle’s medium (-MEM; 12561–049; Invitrogen,
Carlsbad, CA) containing 20% hybridoma-qualified FBS (S11595; At-
lanta Biologicals, Norcross, GA), 2 mM L-glutamine, and antibiotic-
antimycotic solution (1%, 15240–096; Invitrogen; 10,000 U/mL peni-
cillin, 10,000 g/mL streptomycin, 25 ng/mL amphotericin B). Cells
were maintained as low-density cultures plated at 75–150 cells/cm2.
When cultures reached 70%–80% confluence, MSCs were gently lifted
from the dish using 0.25% trypsin and 0.1% EDTA solution (Invitrogen)
and were pelleted at 800g. MSCs were subsequently plated into
150-mm culture dishes at 75–150 cells/cm2. Cultures were maintained
by supplementing the dish with fresh medium every other day.
Engineering Stem Cells Ex Vivo with
Lentiviral Vectors
MSCs were engineered to produce and secrete brain-derived neu-
rotrophic factor (BDNF; rat cDNA) using lentiviral vectors, as previ-
ously reported.42 Briefly, MSCs were plated in six-well plates at a
density of 1000–1200 cells per well and were allowed to adhere for 12
hours. After adhering to the plate, the growth medium was substituted
in each well with -MEM containing 2% FBS and 12 g/mL gelatinous
solid (Sequa-brene, 152667; Sigma-Aldrich, St. Louis, MO). Two sepa-
rate lentiviral constructs encoding BDNF (LV-BDNF; CMV-BDNF-IRES-
GFP) and green fluorescence protein (GFP, LV-GFP; CMV-GFP) were
added simultaneously to MSCs at a multiplicity of infection (MOI) of 15
for each vector. The LV-GFP vector was used as an additional reporter
because of inefficient IRES-GFP expression. A population of control
MSCs was engineered with only the LV-GFP vector at an MOI of 30 to
match the viral titer of the BDNF/GFP-engineered MSCs. Viral particles
were removed after 8 hours of exposure, and medium was changed to
fresh growth medium. Engineered MSCs were subsequently main-
tained as previously described.42
ELISA of BDNF Production
Enzyme-linked immunosorbent assay (ELISA) was used to quantify the
amount of BDNF released from BDNF-MSCs and GFP-MSCs, respec-
tively. A BDNF assay (Emax Immunoassay System, G7610; Promega
Corporation, Madison, WI) was used to detect BDNF in media condi-
tioned for 24 hours by BDNF-MSCs and GFP-MSCs, as reported previ-
ously.42 Initially, 350,000 cells were plated onto 150-mm2 plates and
allowed to adhere for 24 hours. Media were replaced with fresh
growth media, and cells were grown for an additional 24 hours.
Conditioned media (CM) were collected and frozen at 20°C for
subsequent analysis. Anti-BDNF monoclonal antibody in carbonate
buffer was used to coat the wells of a 96-well plate overnight at 4°C.
Wells were incubated with sample buffer and blocker for 1 hour at
room temperature. Samples from CM and a purified BDNF standard
curve (0–500 pg/well) were prepared and incubated in wells on a
shaker for 2 hours. Wells were subsequently washed, an anti-BDNF
polyclonal antibody was added to the wells, and plates were incubated
again on a shaker for 2 hours. An anti-IgY horseradish peroxidase–
conjugated antibody was incubated in the wells on a shaker for 1 hour
at room temperature and subsequently washed. Chromagen substrate
100 L (TMB-One solution; Promega) was added to each well and
reacted for 10 minutes at room temperature. Reactions were stopped
by the addition of 100 L of 1 N HCl per well. Plates were read using
a microplate reader (EL800 Universal Microplate Reader; BioTek In-
struments, Winooski, VT) at 450 nm, and data were analyzed (KC
Junior Software; BioTek Instruments).
Neurotrophin Bioactivity Assay
Primary cultures of rat embryonic day (E) 17 dorsal root ganglia (DRG)
were used to assess the bioactivity of BDNF released from MSCs
because DRGs have been shown to elongate neurites in response to
neurotrophin exposure. Briefly, E17 rat pups were decapitated, rinsed
in ice-cold 70% ethanol, and subsequently placed in ice-cold Dulbec-
co’s modified Eagle’s medium (DMEM). Spinal columns were dissected
through a ventral approach in ice-cold L-15 media (21683-027; Invit-
rogen), and lumbar DRGs were dissected and subsequently pooled.
After dissection, DRGs were rinsed with ice-cold L15 and transferred to
warm DRG growth media containing DMEM, L-glutamine, penicillin-
streptomycin, and 10% FBS. Three DRG explants were transferred in
approximately 75 L media onto a poly-L-ornithine–coated coverglass
placed in 24-well culture plates. DRGs were allowed to adhere for 8
hours, and wells were flooded with experimental media. The experi-
mental media in which DRGs were cultured included MSC growth
media, MSC media conditioned by BDNF-MSCs or GFP-MSCs, respec-
tively, or MSC media containing 50 ng recombinant human BDNF
(rhBDNF; 450-02; PeproTech, Rocky Hill, NJ). Explants were allowed
to grow for an additional 48 hours and subsequently were fixed with
4% paraformaldehyde in 0.1 M PO4 buffer (pH 7.4). Neurite outgrowth
was visualized in cultures by staining with an anti-neurofilament anti-
body (RMO.308, 1:50; Virginia Lee, University of Pennsylvania). Images
were taken and semiquantitatively scored by seven naive observers to
judge the extent and density of neurite outgrowth in each condition.
Each DRG was scored on a scale from 1 to 5, with 1 representing
modest neurite growth in terms of length and density and 5 represent-
ing long, dense neurite arborization from the DRGs. Data from this
analysis were pooled, and statistical analysis was performed.
Laser-Induced Chronic Ocular Hypertension
Chronic ocular hypertension (COH) was induced in the left eye of all
animals, as previously described, while the opposite (right) eyes were
left untouched (no laser surgery or cell transplant was performed) to
serve as a control for all experiments.43 Briefly, rats were anesthetized
with 2.5% isoflurane  100% oxygen; body temperature was main-
tained with a heating pad. Indocyanine green (10 L, 10 mg/mL;
Sigma) was injected into the anterior chamber of the eye at a very slow
rate to avoid abrupt elevation of the IOP from the procedure. Animals
were pretreated with 4% pilocarpine hydrochloride eye drops to in-
crease outflow of the dye into the trabecular meshwork and episcleral
veins. The pilocarpine treatment also caused miosis, which protected
the posterior pigmented structures of the eye from the diode laser
energy (the pigmented iris served as a barrier for any potential stray
energy). Twenty minutes after injection, a diode laser (DioVet; Iridex
Corporation, Mountain View, CA) was used to externally deliver
810-nm energy pulses through a 50-m fiberoptic probe to the region
of the trabecular meshwork and episcleral veins in close proximity to
the limbal region. Careful positioning of the fiberoptic probe ensured
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that the orientation of the laser was away from the pigmented struc-
tures of the retina. Between 50 and 60 laser spots through a 300° range
of the limbal radius (350-mW energy, 1500-ms pulse time) were deliv-
ered. Rats were given acetaminophen (100 mg/kg) and codeine (75
mg/kg) in the drinking water for 7 days after induction to control pain.
Topical antibiotic ointment was applied to the cornea to prevent
excessive drying and corneal ulcers.
Cell Transplantation
Two days after the induction of COH, a small puncture was made in a
dorsolateral location in the eye with a 30-gauge needle. A beveled glass
microelectrode attached to a Hamilton syringe was inserted into this
opening, and approximately 200,000 cells were delivered intravitreally
in 2 L of Earle’s balanced salt solution. A small amount of antibiotic
ointment was applied to the cornea after the transplantation proce-
dure. Cells were only transplanted into eyes that received COH induc-
tion.
Electroretinography
Rats were dark adapted for at least 12 hours before recording. Animals
were initially anesthetized with 3.5% halothane, 30% N2O, and 70% O2
until unresponsive to the righting reflex and were subsequently main-
tained using 1.25% halothane, 30% N2O, and 70% O2 for the duration
of the recording. Pupils were dilated using 2.5% phenylephrine, after
which 1% tropicamide and topical anesthetic (1% proparacaine) was
applied to the cornea. Animals were positioned on a heated sliding
stage to maintain body temperature during anesthesia and recording
sessions. Ground and reference electrodes were placed subcutane-
ously in the tail and forehead of the animal, respectively. A solid
custom-made gold ring recording electrode (Roland Consult, Branden-
burg, Germany) was placed on each eye in contact with the cornea,
and a thin layer of methylcellulose was used to maintain contact
between the cornea and the electrode and to decrease the recording
noise. ERG recordings were performed (Reti-Port system; Roland Con-
sult). Scotopic rod responses (illumination 0.22 cd/m2, cutoff fre-
quency 1–300 Hz; n 8 responses were averaged) were collected first,
followed by scotopic maximum combined response (78 cd/m2, 1–300
Hz; n  8 responses were averaged), oscillatory potentials (78 cd/m2,
200–500 Hz; n 8 responses were averaged), photopic cone response
(21 cd/m2 rod bleaching background light in combination with 78
cd/m2 stimulation, 1–300 Hz; n  8 responses were averaged), and
flicker ERG (78 cd/m2, 1–300 Hz; n  50 responses were averaged).
ERG amplitudes were subsequently analyzed (RETIport32 software;
Roland Consult).
Computerized Pupillometry
Computerized pupillometry was used to assess pupil light reflex (PLR),
as reported previously.43,44 Briefly, animals were anesthetized initially
with 4% halothane, 30% N2O, and 70% O2. A light plane of anesthesia
was maintained with 1% halothane, 30% N2O, and 70% O2 to avoid
suppression of the PLR response caused by the use of higher doses of
anesthetic. A two-channel computerized pupillometer (Neuroptics,
San Clemente, CA) was used to record the movement of the pupil from
the control (nonoperated) eye and the operated eye while a computer-
controlled stimulus light (white light–emitting diodes) was alternately
turned on in front of the control or operated eye (on time, 0.2 seconds;
off time, 5 seconds). The stimulus light intensity used for pupil record-
ings was 78 cd  m2. The change in the pupil area of the control
(nonoperated) eye was evaluated after alternating light stimulus be-
tween the operated and the control eye, whereas pupil responses were
recorded only from the control eye. Pupil responses from the nonop-
erated control eye were expressed as a ratio between PLR response
after illuminating the operated eye and PLR response after illuminating
the control eye (PLR ratio %  operated/control), as previously re-
ported.43,45
Tonometry
Goldmann applanation tonometry with a modified prism for rat record-
ings was used to monitor the IOP in experimental and control eyes, as
previously described.46,47 Animals were anesthetized with a very light
plane of anesthesia (1.0% halothane, 30% N2O, and 70% O2) to de-
crease possible anesthetic effects on the IOP.48 Animals that did not
develop an increase in IOP or that developed ulcerated corneas were
excluded from the study.
Eye Tissue Preparation
Rats were deeply anesthetized with halothane and quickly decapitated
42 days after the induction of COH. Eyes were dissected and fixed with
4% paraformaldehyde (pH 7.4). Optic nerves were dissected from the
eye before fixation and immersed in 2% paraformaldehyde/2% glutar-
aldehyde solution to provide adequate fixation for cross-sectional optic
nerve analysis. Eye globes were sectioned for histology and immuno-
histochemistry analysis.
Optic Nerve Quantification
Optic nerves were collected in 3-mm-thick segments obtained 1 mm
posterior to the globe. Optic nerves were rinsed in cacodylate buffer,
postfixed in 2% osmium tetroxide in cacodylate buffer, dehydrated in
alcohol, and embedded in epoxy resin. Cross-sections (2 m) were cut
with an ultramicrotome, mounted on glass slides, and stained with 1%
paraphenylenediamine. The degree of optic nerve damage was evalu-
ated using a grading scheme similar to that used by other investiga-
tors.6,7,49 Optic nerves were assigned to 1 of 5 grades of damage, with
1 representing healthy optic nerves and 5 representing severely dam-
aged optic nerves. Analysis was performed in a masked manner.
Retinal Ganglion Cell Quantification
Immunohistochemical procedures were used to quantify the number
of RGCs in the retina. Briefly, cryosections were rehydrated in potas-
sium phosphate-buffered solution (KPBS) and incubated in blocking
solution containing 0.1% bovine serum albumin (A9647; Sigma), 0.04%
Triton X-100 (Fisher), and 5% normal donkey serum (017-000-121;
Jackson ImmunoResearch, West Grove, PA) in KPBS. Anti-Brn-3a anti-
body (1:100; Santa Cruz Biotechnology, Santa Cruz, CA) was diluted in
blocker and incubated overnight at room temperature. Tissue was
rinsed with KPBS containing Triton X-100, and incubated with Cy-3–
conjugated secondary antibodies for 2 hours. After rinses, 4, 6-di-
amidino-2-phenylindole, dilactate (DAPI, 1 g/mL, D3571; Sigma) was
applied for 30 minutes at room temperature to visualize nuclei. Slides
were mounted with anti-fade mounting media (Gelmount; Sigma) and
sealed. Negative controls were processed in parallel by omission of the
primary or secondary antibody. Tissue was imaged using a microscope
(Microphot; Nikon, Melville, NY). Micrographs were prepared using
commercial software (Photoshop, version 9.0 [Adobe, San Jose, CA]
and Macromedia Freehand, version 10.0 [Macromedia, San Francisco,
CA]). Quantification of RGCs was performed by counting Brn-3a–
immunolabeled cells in serial sections (five per eye) of control and
hypertensive rat eyes.
Statistical Analysis
Statistical analysis was performed by using Student’s t-test, paired t-test,
and one-way ANOVA with Bonferroni posttest (as indicated in the text)
graphing and statistics software (GraphPad, San Diego, CA). P  0.05
was considered significant.
RESULTS
Evaluation of BDNF Production from MSCs
Lentiviral vectors were used to engineer MSCs to produce the
neurotrophic factors BDNF and GFP or GFP alone. The infec-
tion rate of the lentiviral vectors was evaluated by counting
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DAPI-stained cell nuclei and GFP-positive cells in eight fields.
The observed infection rate in our experiments was 99.05% 
0.65%. We have shown that MSCs engineered to express the
BDNF construct displayed intense anti-BDNF immunoreactivity
(IR) in the perinuclear area within the cell body (Fig. 1A). To
ensure that the intense IR was due to transduction by a viral
construct, anti-GFP antibodies were used to identity GFP pro-
duced by the IRES-GFP site and to examine the cellular local-
ization of BDNF immunoreactivity (Figs. 1B, 1C). In contrast,
MSCs transduced with LV-GFP vectors displayed less intense
BDNF immunoreactivity than BDNF-MSCs but expressed high
levels of GFP (Figs. 1D–F), demonstrating BDNF upregulation
in MSCs is due to BDNF gene delivery and not an artifact of
general lentiviral transduction.
To determine whether transduced MSCs were capable of
secreting BDNF, ELISA analysis of media conditioned by engi-
neered MSCs was performed. Secretion of BDNF from control
GFP-MSCs was 0.97  0.52 ng BDNF/mL per 106 cells/day,
which was significantly less than 41.40  1.32 ng/mL per 106
cells/day secreted by lentiviral transduced BDNF-MSCs (Fig. 2A;
P  0.0001, Student’s t-test). Rat embryonic DRG cultures
were used to investigate the bioactivity of the secreted BDNF,
as we have previously described.42 The length and density of
neurites extending from DRGs cultured in control media, or
media conditioned by engineered MSCs, was assessed and
quantified in the masked manner previously described.42 On
treatment with media only, DRGs elaborated relatively short
neurites (Figs. 2B, 2C). A similar level of modest outgrowth was
FIGURE 1. MSCs engineered with
lentiviral vectors express GFP
(green) and BDNF (red). MSCs trans-
duced with lentiviral BDNF vectors
(A–C) showed increased expression
of BDNF (A, arrows). Merged image
(C) demonstrates perinuclear local-
ization of BDNF immunoreactivity in
BDNF-MSCs (arrows). Control MSCs
transduced with lentiviral GFP vec-
tors (D–F) show diffuse BDNF immu-
noreactivity throughout the cell (D,
arrows). Robust GFP expression is
apparent using conventional fluores-
cence microscopy (E). Merged image
(F) demonstrates the BDNF localiza-
tion in GFP-MSCs.
FIGURE 2. MSCs secrete bioactive
BDNF. ELISA analysis revealed BDNF-
MSCs secrete 41.40 1.32 ng BDNF/
106 cells/day, which was signifi-
cantly higher than control GFP-MSCs
secreting 0.97  0.52 ng BDNF/106
cells/day (A). Media conditioned by
BDNF-MSCs or GFP-MSCs were col-
lected and applied to E17 rat dorsal
root ganglia explant cultures to assay
and quantitate BDNF bioactivity (B).
DRGs were treated with MSC growth
media (C), media conditioned by
GFP-MSCs (D) or BDNF-MSCs (E), or
MSC growth media supplemented
with 50 ng rhBDNF (F). Montage im-
ages of DRGs were collected and sub-
sequently scored by naive observers
(B). No significant difference was ob-
served in the modest outgrowth of
neurites induced by MSC media only
(C) or GFP-MSC–conditioned media
(B, D; P  0.05). BDNF-MSC condi-
tioned media induced robust out-
growth of neurites from DRGs (E)
and did not differ significantly from
DRG outgrowth induced by rhBDNF-supplemented media (B, F; P 0.05). Each group of DRGs exposed to BDNF, however, had significantly more
neurite outgrowth than each of the control groups (P  0.05). Scale bar, 400 m (C–F). GFP-MSC CM, GFP-MSC conditioned media; BDNF-MSC
CM, BDNF-MSC conditioned media; rhBDNF, recombinant human brain-derived neurotrophic factor. *P  0.05.
IOVS, June 2011, Vol. 52, No. 7 Stem Cell Treatment for Glaucoma 4509
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/933461/ on 05/23/2017
observed in DRGs treated with GFP-MSC–conditioned media
(CM) (Fig. 2D), and statistical analysis revealed no significant
difference between these two groups (Fig. 2B; P  0.05,
one-way ANOVA with Bonferroni posttest). In contrast, DRGs
that were treated with BDNF-MSC CM (Fig. 2E) and DRGs
treated with 50 ng rhBDNF (Fig. 2F) displayed extensive neu-
rite outgrowth and often elaborated processes in excess of 1.6
mm from the explant. Neurite outgrowth in DRGs treated with
BDNF-MSC CM is similar in those treated with rhBDNF (P 
0.05, one-way ANOVA with Bonferroni posttest). Both these
groups displayed significantly greater neurite outgrowth scores
than DRGs treated with media or GFP-MSC CM (Fig. 2B, P 
0.05, one-way ANOVA with Bonferroni posttest). Together
these results demonstrated that the MSCs transduced with the
lentiviral BDNF vectors were capable of producing and secret-
ing BDNF with potent neurite outgrowth-promoting bioactiv-
ity.
Evaluation of the IOP in a Rat Model of COH
The rat model of COH was used to evaluate the possible
beneficial effects of MSC transplantation on retinal and optic
nerve function and structure. The IOP for eyes of BDNF-MSC–
and GFP-MSC–treated animals before COH induction were not
significantly different: 14.0  0.5 and 15.0  0.5 mm Hg,
respectively (Fig. 3A; P 0.4523, Student’s t-test). A significant
increase in IOP was observed after the induction of COH (Fig.
3A). The IOP for BDNF-MSC– and GFP-MSC– transplanted eyes
10 days after induction was 22.6  0.9 and 23  1 mm Hg,
respectively, and was not significantly different between
groups (Fig 3A; P  0.8167, Student’s t-test). The IOP was
significantly higher in laser-treated eyes than in fellow control
eyes, which were 13.4  0.6 for BDNF-MSC fellow eyes (Fig.
3A; P  0.0001, paired t-test) and 14  0.6 mm Hg for
GFP-MSC fellow eyes (Fig. 3A; P  0.0001, paired t-test). The
increased IOP in laser-treated eyes was also apparent 25 days
after induction: BDNF-MSC, 18.8  0.6 mm Hg; GFP-MSC,
19.6  0.8 mm Hg; fellow control eyes, 13.3  0.4 (P 
0.0001, paired t-test) and 13.5  0.4 mm Hg (P  0.0001,
paired t-test), respectively (Fig. 3A). The increased IOP re-
turned to near baseline levels by 42 days after induction, with
IOPs of 14.7  0.7 and 14.4  0.5 mm Hg for BDNF-MSC and
GFP-MSC transplant recipient eyes, respectively. Additionally,
these values were not significantly different from those of
fellow eyes for BDNF-MSC–treated (13.4  0.4 mm Hg; P 
0.1579) and GFP-MSC–treated (13.2  0.4 mm Hg; P  0.0749)
animals. To ensure there was no significant difference in the
relative change in IOP between BDNF-MSC– and GFP-MSC–
treated eyes, the difference was calculated between the fellow
IOP and the experimental eye IOP (IOP). This analysis revealed
no significant difference in the baseline IOP (P  0.5541) or at
10 (P  0.5350), 25 (P  0.7570), or 42 (P  0.4782) days after
the elevation of IOP (Fig. 3B). The calculated IOP integral for
COH eyes treated with BDNF-MSCs (195.5 19.59 mm Hg days)
and GFP-MSCs (200.6 18.50 mm Hg days) was not significantly
different (P  0.8512, Students t-test).
Analysis of Retinal and Optic Nerve Function:
ERG and PLR Analysis
Electroretinography analysis revealed significant preservation
of retinal electrical activity in COH eyes that received BDNF-
MSC transplants compared with those experimental eyes that
received control GFP-MSCs. At 20 days after transplantation,
BDNF-MSC–recipient animals had significantly greater ERG am-
plitudes (amplitudes were expressed as a ratio between oper-
ated eye and fellow control eye ERG amplitudes) compared
with GFP-MSC–recipient animals for the rod b-wave (BDNF,
41.21%  9.90%; GFP, 18.37%  4.70%; P  0.0403, Student’s
t-test), cone b-wave (BDNF, 58.49%  9.60%; GFP, 35.26% 
4.22%; P  0.0315), maximum combined b-wave (BDNF,
53.68%  10.39%; GFP, 25.09%  5.76%; P  0.0064), and
FIGURE 3. Laser cauterization of trabecular meshwork and episcleral
veins resulted in the development of COH. (A) Laser cauterization
resulted in the significant IOP increase in operated eyes at 10 and 25
days after surgery (*P  0.05). BDNF-MSCs, hypertensive eyes that
received transplants of BDNF-producing MSCs; BDNF-Fellow, opposite
(control eye) that did not receive laser surgery or an MSC transplant;
GFP-MSCs, hypertensive eyes that received transplants of GFP-express-
ing MSCs not modified to produce BDNF; GFP-Fellow, opposite (con-
trol eye) that did not undergo laser surgery or MSC transplantation. (B)
Statistical analysis revealed no difference in the IOP (IOP operated
eye  IOP control eye) between BDNF-MSC and GFP-MSC groups at
different time points during the experiment (mean  SEM). (C) Anal-
ysis of the IOP integral revealed no significant difference in the IOP
integral between BDNF-MSC– and GFP-MSC–treated groups.
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flicker amplitude (BDNF, 51.44%  9.81%; GFP, 31.17% 
4.08%; P  0.0447, Fig. 4A). There was not a significant
difference in the ERG amplitude ratios for the cone a-wave
(BDNF, 72.10%  15.5%; GFP, 85.46%  17.20%; P  0.8205)
or the maximum combined a-wave (BDNF, 49.35%  13.58%;
GFP, 26.94%  5.34%; P  0.0900) amplitudes. Analysis of
oscillatory potentials did not reveal a statistically significant
difference between BDNF-MSC and GFP-MSC–treated animals
despite a trend toward higher amplitudes in the BDNF-treated
group (BDNF, 56.65%  12.20%; GFP, 24.28%  4.62%; P 
0.146; Fig. 4A).
Sustained preservation of ERG responses was also observed
at 40 days after transplantation for the rod b-wave (BDNF,
43.23%  7.88%; GFP, 20.88%  5.41%; P  0.0245), maxi-
mum-combined b-wave (BDNF, 61.16% 8.45%; GFP, 34.71%
8.66%; P  0.0349), cone b-wave (BDNF, 59.30%  7.99%;
GFP, 29.33%  5.05%; P  0.0033), and flicker responses
(BDNF, 68.58%  7.54%; GFP, 40.57%  5.58%; P  0.0054;
Fig. 4B). There was not a significant difference in the ERG
amplitude ratios for any measured a-wave parameters, cone
(BDNF, 74.02% 14.09%; GFP, 78.51% 11.31%; P 0.8035) or the maximum combined a-wave (BDNF, 61.16%  14.36%;
GFP, 34.75%  6.48%; P  0.8035) amplitudes. The oscillatory
potentials in BDNF-MSC– and GFP-MSC–treated animals were
not significantly different (BDNF, 51.01%  7.74%; GFP,
32.11% 7.21%; P 0.0869). Computerized pupillometry was
used to assess the combined function of the different retinal
layers and the optic nerve. There was a significantly better
afferent pupil response in BDNF-MSC–treated eyes (63.00% 
11.39%) than in GFP-MSC–treated eyes (31.81%  9.63%; P 
0.0343) at 42 days after transplantation (Fig. 5).
MSCs Survive after Transplantation into
Chronically Hypertensive Eyes
Examination of the ocular sections demonstrated that MSCs
were capable of surviving in hypertensive eyes with 17.62% 
2.52% (BDNF-MSC) or 15.89%  3.73% (GFP-MSC) survival
rates at the termination of the experiment (BDNF-MSC,
35,233  5041 cells; GFP-MSC, 31,780  7469 cells). MSCs
were counted per tissue section at the termination of the
experiment. Transplanted MSCs were capable of surviving in
COH eyes and were predominantly found adjacent to the
ganglion cell layer (GCL) (Figs. 6A–C), integrated into inner
retinal layers (Figs. 6D–F), or in the vitreous of transplanted
FIGURE 4. Transplantation of BDNF-MSCs preserved retinal function
in COH eyes. Retinal electrical activity was significantly higher in
BDNF-MSC–treated eyes than in GFP-MSC–treated eyes at 20 (A) and 40
(B) days after transplantation for the rod b-wave, cone b-wave, maxi-
mum combined b-wave (Max b-wave), and flicker responses. Oscilla-
tory potentials (OPs) were not significantly different between BDNF-
MSC– and GFP-MSC–treated animals. *P  0.05.
FIGURE 5. Computerized pupillometry analysis of the pupil light re-
sponse at 42 days after transplantation showed significantly better
pupil constriction in BDNF-MSC–treated eyes than in GFP-MSC–treated
eyes (*P  0.05). The pupil light reflex is presented as a ratio of
constriction amplitudes measured from the control (nonoperated) eye
after illumination of the operated and control eyes.
FIGURE 6. MSCs survive after transplantation into hypertensive eyes.
Lentiviral-transduced MSCs were detected in the retina using an anti-
GFP antibody at the end of the experiment (A, D). MSCs (BDNF-MSCs,
A–C; GFP-MSCs, D–F) were predominantly detected in the retinal
ganglion cell layer (B, C) and the inner retinal layers at (E, F). Auto-
fluorescence was detected in the outer retina associated with photo-
receptor outer segments (A–C). DIC, differential interference contrast.
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eyes 42 days after transplantation (Supplementary Fig. S1,
http://www.iovs.org/lookup/suppl/doi:10.1167/iovs.11-7346/-/
DCSupplemental). Immunohistochemical analysis of retinal tis-
sue sections collected from eyes with chronic hypertension
that underwent BDNF-GFP-MSC transplantation at the termina-
tion of the experiment showed strong BDNF and TrkB expres-
sion within the retina (Supplementary Figs. S2A, S2B, http://
www.iovs.org/lookup/suppl/doi:10.1167/iovs.11-7346/-/
DCSupplemental).
Retinal Ganglion Cell and Optic
Nerve Quantification
Retinal ganglion cells (RGCs) were identified based on immu-
noreactivity for the RGC-specific transcription factor Brn3a50
and were counted to determine the level of neuroprotection
provided to RGCs from BDNF-MSCs. Analysis of baseline mea-
surements of the numbers of Brn-3a-IR RGCs in the GCL in
fellow (nonoperated) eyes for BDNF-MSC–treated (200.8 
40.1/section) and GFP-MSC–treated (176.6  40/section) rats
revealed no significant difference between groups (Figs. 7A,
7B, 7G; P 0.6743; Student’s t-test). Quantification of Brn3a-IR
RGCs in BDNF-MSC–treated eyes revealed a significantly higher
number of RGCs (112.2  19.3/section) than in GFP-MSCs
(52.2  11.5/section; Figs. 7C–G; P  0.0106, Student’s t-test).
Statistical analysis revealed that both groups had significantly
fewer RGCs than fellow control eyes (Fig. 7G; BDNF, P 
0.0142; GFP, P  0.0056; both paired t-tests).
Optic nerve integrity was examined to compare the optic
nerves of the untreated control eye with those of the BDNF-
MSC– and GFP-MSC–transplanted eyes. Masked analysis re-
vealed no significant difference in the appearance (grade) of
optic nerves from COH eyes that received the BDNF-MSCs
(2.5 0.34; Fig. 8A) and their fellow control eyes (1.73 0.38;
Figs. 8B, 8E; P  0.0948, paired t-test). In contrast, there was
a significant difference in optic nerve integrity when compar-
ing optic nerves of COH eyes that received the GFP-MSCs
(3.25  0.37, Fig. 8C) with those of their fellow control eyes
(1.08  0.07; Figs. 8D, 8E; P  0.001). However, analysis of
optic nerve scores between BDNF-MSC–treated (2.5  0.34)
and GFP-MSC–treated (3.25  0.37) eyes did not reach a
statistically significant difference, despite a trend toward
higher values in the BDNF-MSC group (P  0.1493).
DISCUSSION
Current medical and surgical interventions for glaucoma are
focused on IOP reduction and the modification of factors, such
as blood pressure, to improve optic nerve blood flow and to
prevent the progression of vision loss. However, visual field
deficits continue to develop in many patients despite adequate
IOP control, which dictates a need for the development of
novel therapeutic approaches that may provide direct protec-
tion of optic nerve function and structure. Different neu-
rotrophic growth factors have been tested in animal models of
glaucoma and optic nerve damage as possible therapeutic
agents for preserving the function and structure of damaged
tissues, with a particular focus on the use of BDNF.37,40,44,51–55
RGCs56 and astrocytes57 have an intrinsic capacity to produce
BDNF, and the retina can also receive BDNF from the thalamus
by way of retrograde transport. BDNF binds predominantly to
TrkB receptors, which activate prosurvival signaling cascades
by dimerization or internalization58 of the receptor. It has been
shown that TrkB expression is decreased by negative feedback
loops59,60 after bolus injections of BDNF, which could attenu-
ate any potential benefit derived from delivering large amounts
of supplemental BDNF to the retina.
FIGURE 7. BDNF-MSC–transplanted cells served to protect Brn3a-IR
RGCs in COH eyes. BDNF-MSC–treated COH eyes had significantly
fewer Brn3a-IR cells per section than untreated fellow eyes (A–D; P 
0.05). GFP-MSC–treated COH eyes also had significantly fewer Brn3a-IR
cells per section than untreated fellow eyes (E, F; P 0.01). However,
quantitative analysis of BDNF-MSC– and GFP-MSC–treated eyes re-
vealed significantly more Brn3a-IR cells per section in BDNF-MSC–
treated eyes than in GFP-MSC–treated COH eyes (G; *P  0.05).
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In our study, we used MSCs to deliver a constant, low level
of BDNF and demonstrated that this approach has potential for
functional and structural retinal protection in eyes with
chronic hypertension.
We have previously demonstrated that chronic intravitreal
release of low BDNF doses from polymer microspheres does
provide effective functional protection in rat retinas exposed
to the aggressive acute elevation of IOP.44 Other groups have
demonstrated similar positive effects in terms of decreased
optic nerve damage in a rat model of COH54 and the DBA-2J
mouse model of glaucoma55 using long-term delivery of rela-
tively low doses of neurotrophic growth factors. Approaches
that use viral-mediated gene therapy have also been shown to
be successful in preventing RGC degeneration in rodent mod-
els of optic nerve transection38 and ocular hypertension,37
whereas the transplantation of naive MSCs into rats with COH
also showed positive effects.27 Although results from these
studies showed anatomic preservation of RGCs and optic nerve
structure, the effects on visual system functional status have
not been addressed.
In this study, we have used a similar approach with the
particular goal of evaluating the functional properties of
chronic hypertensive rat eyes after BDNF-MSC transplantation.
We have shown that MSCs can be used as cellular vehicles for
delivering neuroprotective proteins to the retina and are read-
ily transformed using lentiviral vectors to secrete bioactive
BDNF. Importantly, transplanted MSCs are capable of surviving
in eyes with COH and do not appear to cause any undesirable
side effects. Aside from the ability to survive for prolonged
periods of time in hypertensive eyes, MSCs can be used in the
form of autologous transplants, which would dramatically re-
duce risks associated with the rejection of transplanted cells
and the potential transmission of infectious agents between
donors and recipients.
One important finding of this study is that BDNF-MSC trans-
plants confer robust protection of retinal and optic nerve
function and, to some extent, optic nerve structure. Although
structural preservation may provide potential evidence of the
successful therapeutic approach, ultimately the functional sta-
tus of damaged tissue dictates potential for the preservation or
recovery of visual function. This study clearly demonstrated
that chronic low-dose delivery of BDNF results in significant
preservation of retinal and optic nerve functional parameters
observed by ERG and PLR analysis, despite relatively small
effects on optic nerve structural protection (observed by grad-
ing of optic nerve cross-sections), which might have been
FIGURE 8. Effect of BDNF-MSC
transplants on optic nerve integrity
in COH eyes. Optic nerves were
assigned to 1 of 5 grades of damage,
with 1 representing healthy optic
nerves and 5 representing severely
damaged optic nerves. No significant
difference in optic nerve grades was
observed between the optic nerves
of COH eyes treated with BDNF-
MSCs (A) and the fellow optic nerves
(B). A significant difference was ob-
served between optic nerves of COH
eyes treated with GFP-MSCs (C) and
control optic nerves of fellow, un-
treated eyes (D, P  0.001). How-
ever, analysis of optic nerve scores
between BDNF-MSC– and GFP-MSC–
treated eyes did not reveal a statisti-
cally significant difference (E).
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limited by the semiquantitative nature of the grading scale
method.
In conclusion, the use of these easily obtained, adult-de-
rived stem cells as vectors to deliver neuroprotective proteins
may become an attractive therapeutic approach for the treat-
ment of chronic neurodegenerative retinal and optic nerve
diseases in the future.
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